Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 2, 2017 in Diabetes mellitus | 0 comments

In a nutshell

This study examined whether SGLT-2 inhibitors were effective as a complement to insulin therapy in type 1 diabetes. The authors concluded that SGLT-2 Inhibitors had the potential to be a complementary treatment option.

Some background

Patients with type 1 diabetes (T1D) do not produce enough insulin (a hormone) to control their blood sugar levels. They thus need to be treated with additional insulin in order to manage their blood sugar. Insulin therapy can sometimes, hower, cause weight gain and / or hypoglycemia (dangerously low blood sugar). In recent years, new complementary treatments (which aim to reduce side effects) have become available. Sodium glucose co-transporter 2 (SGLT-2) inhibitors are a possible complementary treatment option. They have been effective in treating patients with type 2 diabetes. It is unclear, however, how SGLT-2 Inhibitors affect patients with T1D

Methods & findings

This study investigated whether SGLT-2 inhibitors were a safe and effective add-on treatment for T1D. It summarized the results of seven clinical trials, including 581 patients. 
Compared with those not treated with SGLT-2 inhibitors, those treated with SGLT-2 inhibitors (in addition to insulin) reduced their fasting blood sugar by 0.69 mmol/L (blood glucose after a period without food or drink)Those on SGLT-2 inhibitors also reduced their HbA1C (average blood glucose over 3 months) by 0.37%, their bodyweight by 2.54kg and their total daily insulin dose by 6.22IU.
There were no differences in events of hypoglycemia seen in each group. However, 16 patients treated with SGLT-2 inhibitors expierenced diabetic ketoacidosis (a potentially dangerous condition resulting in extremely high blood sugar).

The bottom line

This study concluded that SGLT-2 Inhibitors may be a useful "add-on" treatment option for patients with T1D.

The fine print

Larger and longer trials are needed. Patients with kidney- or heart disease were not examined, so treatment may not be suitable in these cases. Furthermore, the majority of the patients examined had initially relatively well controlled blood sugar and/or were young; SGLT-2 Inhibitiors might not be as effective for other patients. 

Published By :

Scientific reports

Date :

Mar 09, 2017

Original Title :

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.

click here to get personalized updates